Advanced search
Publication Cover
Modern Rheumatology Volume 31, 2021 - Issue 2
Journal homepage
188
Views
5
CrossRef citations to date
0
Altmetric
Connective Tissue Diseases and Related Disorders

Iguratimod treatment reduces disease activity in early primary Sjögren's syndrome: An open-label pilot study

Hua Chena Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;b Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, ChinaORCID Iconhttps://orcid.org/0000-0002-0641-2837
ORCID Icon,
Xuan Qia Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;b Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China
,
Yuan Lia Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;b Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China
,
Qing Wuc Department of Stomatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
,
Qun Shia Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;b Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China
,
Li Wanga Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;b Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China
,
Jing Lia Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;b Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China
,
Lidan Zhaoa Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;b Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China
,
Li Zhanga Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;b Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China
,
Xinyao Zhoud Department of Rheumatology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
,
Yunyun Feia Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;b Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China
,
Jinjing Liua Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;b Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China
,
Jinmei Sua Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;b Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China
,
Di Wua Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;b Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China
,
Yunjiao Yanga Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;b Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China
,
Hui Jianga Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;b Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China
,
Xiaofeng Zenga Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;b Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China
,
Fengchun Zhanga Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;b Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China
&
Yan Zhaoa Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;b Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, ChinaCorrespondence[email protected]
 show all
Pages 394-398 | Received 19 Dec 2019, Accepted 17 Jun 2020, Published online: 03 Aug 2020

References

  • Fox RI. Sjogren's syndrome. Lancet. 2005;366(9482):321–31.
  • Saraux A, Pers J-O, Devauchelle-Pensec V. Treatment of primary Sjögren syndrome. Nat Rev Rheumatol. 2016;12(8):456–71.
  • Li Y, Zhang K, Chen H, Sun F, Xu J, Wu Z, et al. A genome-wide association study in Han Chinese identifies a susceptibility locus for primary Sjögren's syndrome at 7q11.23. Nat Genet. 2013;45(11):1361–5.
  • Lessard CJ, Li H, Adrianto I, Ice JA, Rasmussen A, Grundahl KM, et al.;for UK Primary Sjögren's Syndrome Registry. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren's syndrome. Nat Genet. 2013;45(11):1284–92.
  • Duan XW, Zhang XL, Mao SY, Shang JJ, Shi XD. Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial. Clin Rheumatol. 2015;34(9):1513–9.
  • Du F, Lu LJ, Fu Q, Dai M, Teng JL, Fan W, et al. T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis. Arthritis Res Ther. 2008;10(6):R136.
  • Ye Y, Liu M, Tang L, Du F, Liu Y, Hao P, et al. Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis. Arthritis Res Ther. 2019;21(1):92.
  • Jiang W, Zhao Y, Lin H, Liu Y, Chen J. Clinical observation on treatment of primary Sjogren's syndrome by Iguratimod. Med J West China. 2014;26(6):719–21,724 (in Chinese).
  • Xu D, Lu X, Cui P, Ma S. Comparison of the efficacy and safety of iguratimod and hydroxychloroquine in the treatment of Sjogren's syndrome. Chin J Dific Compl Cas. 2017;16(9):915–8 (in Chinese).
  • Li C, Li R, Liu H, Cheng C, Zhao T. Clinical effect of methylprednisolone combined with iguratimod in the treatment of primary Sjogren's syndrome and its effect on the levels of serum immunoglobulin. China Pharm. 2018;27(14):35–7 (in Chinese).
  • Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al.; European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554–8.
  • Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis. 2010;69(6):1103–9.
  • Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, et al. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Ann Rheum Dis. 2011;70(6):968–72.
  • Wang X, Yuan X, Wang Q, Y Z, Li X, Wang G, et al. Clinical study of effectiveness and safety of iguratimod in treating primary Sjogren's syndrome. Chin J Dis Control Prev. 2018;22(1):75–8,84 (in Chinese).
  • Gao H, Zhang X-Y, Zhang X-W, Zhanguo L. Efficacy and safety of iguratimod in patients with primary Sjogren syndrome: a follow-up study. Ann Rheum Dis. 2019;78:S1696.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.